Page 2 - Biosimilar Development News Today

Pharmaceutical Excipients Market Forecast to reach US$10.4 billion by 2027 after Growing at a CAGR of 5.9 % during the Forecast Period 2022-2027

Pharmaceutical Excipients Market Forecast to reach US$10.4 billion by 2027 after Growing at a CAGR of 5.9 % during the Forecast Period 2022-2027

2021 saw several important milestones in the biosimilars space, including the much anticipated first interchangeable designations by FDA and the approval of the first ophthalmology...

After reflecting upon the events of the past twelve months, Patent Docs presents its 15th annual list of top patent stories. For 2021, we identified nine stories that were covered on...

As 2021 comes to a close, Big Molecule Watch reviews the top five biosimilar regulatory developments of the year... President Biden Signs Orange Book Transparency Act - ...

On September 30, 2021, the European Medicines Agency (EMA) released a report entitled “Tailored Scientific Advice for Biosimilar Development,” describing results from its pilot program...

On September 20, 2021, the FDA issued a revised final guidance for industry entitled “Questions and Answers on Biosimilar Development and the BPCI Act” and a third revision to its draft...

/PRNewswire/ -- The "Biopharmaceutical Contract Manufacturing Market by Type of Product, Scale of Operations, Expression System, Company Size, Biologics and...

for those of you looking to catch-up on biosimilars in 2020 and what these experts are most excited about for the year(s) ahead. As the Editorial Board explores which challenges are ahead for 2021, it’s reassuring to note that sustainability is increasingly entering the U.S. biosimilars conversation. As you’ll note in this installment, there are several particularly passionate calls-to-action for companies to confront misinformation, collaborate with stakeholders, and to refine their comme...

To embed, copy and paste the code into your website or blog: As 2020 comes to a close, Big Molecule Watch once again reviews the top developments in the biologics and biosimilars space for 2020.  Please keep an eye out this week for posts identifying the most important regulatory, market, and legal developments impacting biosimilars.  We start today with our picks for the most significant U.S. regulatory developments related to biosimilars in 2020: 1.FDA and FTC Announced Collaboration to Sup...